(NASDAQ: CNTA) Centessa Pharmaceuticals's forecast annual revenue growth rate of 116.5% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Centessa Pharmaceuticals's revenue in 2025 is $15,000,000.On average, 5 Wall Street analysts forecast CNTA's revenue for 2025 to be $2,004,281,610, with the lowest CNTA revenue forecast at $2,004,281,610, and the highest CNTA revenue forecast at $2,004,281,610. On average, 2 Wall Street analysts forecast CNTA's revenue for 2026 to be $6,793,312,089, with the lowest CNTA revenue forecast at $6,237,591,608, and the highest CNTA revenue forecast at $7,349,032,570.
In 2028, CNTA is forecast to generate $9,192,971,651 in revenue, with the lowest revenue forecast at $8,631,772,800 and the highest revenue forecast at $9,754,170,502.